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Abstract Background Salivary fistulas are a well-known
sequel of parotidectomy, and successful treatment with bot-
ulinum toxin has been demonstrated in individual cases.
Here, we report on 12 patients with fistulas treated follow-
ing parotidectomy for various indications.
Methods and results Injection of botulinum toxin type A into
the residual gland tissue was the initial treatment. After early
intervention (within 6 weeks after development of the fistula),
only one fistula remained (9 of 10 fistulas treated early only
with botulinum toxin). One patient with early intervention did
not want to wait for the botulinum toxin treatment to take
effect and demanded early surgical revision, which was suc-
cessful. In one patient with a permanent fistula, botulinum
toxin treatment began 420 days after the operation and was
unsuccessful. No side effects were evident after the treatment.
Conclusion In summary, botulinum toxin injections into the
parotid tissue remaining after surgery appear to be an effec-
tive treatment for salivary fistulas following parotidectomy.
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Botulinum toxin . Long-term results
Background
Salivary fistulas can occur after parotid gland surgery [1, 5, 7,
8, 11, 14, 15]. This occurs in 4 % of the cases in our clinic
[8], but incidence rates of up to 14 % have been reported [11,
12]. A number of different therapeutic approaches have been
described for the treatment of parotid fistulas subsequent to
parotid gland surgery [2, 11, 15]. In recent years, treatment
with botulinum toxin (BoNT) has gained increasing recogni-
tion [3, 4, 6, 9, 10, 12, 13, 16]. Reports in the literature refer
mainly to early fistulas after parotid gland surgery, which had
been treated without delay, i.e., before complete wound heal-
ing. However, these reports of successful treatment with
BoNT are based only on individual case reports [3, 4, 6, 9,
10, 12, 13, 16].
Permanent fistulas (see example in Fig. 1) that persist
after complete wound healing after the parotid gland proce-
dure are a subgroup that requires special attention. They are
difficult to treat [1, 6, 16], and preventive measures should
be initiated early on.
This retrospective analysis describes our experience in the
treatment of postoperative parotid fistulas with botulinum
toxin A. It presents the flow diagram of our current therapy
as well as special aspects that have received no mention in the
literature, such as the success rate in a larger patient collective.
Patients and methods
In the period from 2006 to 2011, we treated 12 patients (see
Table 1 for characteristics of the cohort) with the clinical
diagnosis of a salivary fistula subsequent to surgery on the
parotid gland. The fistulas present with repeated leakage of
saliva from the caudal, pre-, or subauricular suture in the
neck region, particularly after meals. There were seven male
and five female patients. The indication for surgery was
cystadenolymphoma in seven patients, pleomorphic adeno-
ma in two patients, one parotid cyst, one lymphoma in a
HIV-positive patient, and one undefined infiltrative process
(explorative parotidectomy). The surgical procedure was a
superficial parotidectomy in 11 patients and a partial super-
ficial parotidectomy in one.
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There is no clear definition in the literature of when a
salivary fistula subsequent to parotid surgery should be clas-
sified as “permanent”. However, clinical experience shows
that some patients have a salivary fistula that does not close
by itself, which is a challenging starting condition for treat-
ment. Because of the special problems associated with
persisting fistulas, we considered it advisable to differentiate
between “early fistulas” (BoNT administration earlier than
6 weeks after parotid gland surgery with potentially adaptable
wound tissue) and “permanent fistulas” (BoNTadministration
later than 6 weeks after surgery). According to this classifica-
tion, our treatment population consisted of 11 patients with
“early fistulas” and one with a “permanent fistula”.
As described previously [3], BoNT was injected under
ultrasound guidance into the postoperatively remaining
glandular tissue to selectively reduce secretory activity. This
is similar to the procedure described by other authors [4, 6].
The total dose of BoNT (Botox®, Allergan, 100 units (U)
dissolved in 4 ml normal saline) was between 10 and 40 U
depending on the size of the remaining glandular compart-
ment. The individual doses were 10 U in one patient, 15 U in
two, 20 U in four patients, 25 U in two, 30 U in five, and 40
U in one patient (average dose was 23.3 U). It was injected
into the gland at two to three sites. Because of persisting
leakage of saliva after the first injection, three patients
obtained two injections: 25 and 15 U, 20 and 20 U, and 30
and 15 U, respectively. The time interval between the two
injections amounted to 7, 77, and 111 days.
Botulinum toxin A was injected into the remaining tissue
between 9 and 420 days after parotidectomy. One patient
(number 5 in Table 1) who was injected with 30 U of BoNT
7 days after the appearance of the fistula did not want to wait
for the BoNT to take effect and demanded immediate surgical
revision of the fistula 42 days after the initial operation. The
procedure was performed as wished, although we did not
consider it absolutely indicated since wound healing was not
yet complete. The fistula was resected under the microscope,
and an additional 30 U of Botox® was applied intraopera-
tively to the remaining glandular tissue.
Results
The fistulas described in this report appeared between 2 and
38 days (average 14.0 days) after the parotid gland surgery.
In 9 of the 12 patients, treatment with BoNT led to a
complete closure of the fistula without any further surgical
measures. The documented time of closure was 2 to 5 weeks
(average was 3.3 weeks) after the BoNT injection.
The flow of saliva to the cheek and neck decreased
rapidly and markedly after the injection. No complications
due to the BoNT injections were seen.
In one patient (number 1 in Table 1), neither the early
injection of BoNT (30 and 15 U) nor the subsequent surgical
fistula excision and intraoperative BoNT application were
able to close the fistula. Radiation therapy (total dose of
30 Gy) and renewed excision were ultimately successful [1].
The fistula of the patient (number 5 in Table 1) who did not
want to wait for the potentially positive effect of the BoNT
injection was closed by microsurgical fistula extirpation and
intraoperative BoNT injection.
The treatment of a patient (number 11 in Table 1) with a
persisting fistula with BoNT injections 420 days after paro-
tidectomy (20 units and 20 units) and surgical revision was
unsuccessful. Because of the great emotional strain, he was
given low-dose radiation therapy that was eventually
successful.
In summary, the data presented here with their special
aspects show that salivary fistulas were healed in 9 of 10
patients (90 %) with BoNT treatment alone when treatment
started early after the development of the fistula and time
was allowed for the treatment to take effect. Treatment was
unsuccessful in only one patient of this group.
Discussion
Salivary fistulas are a well-known complication that can
occur after parotid gland surgery. Numerous medical and
surgical interventions have been described as therapeutic
options in the literature [11, 12]. The most important thera-
peutic principle is to reduce the secretion of the remaining
glandular tissue in order to both alleviate the symptoms and
facilitate closure of the fistula. This goal can be attained in a
minimally invasive manner with botulinum toxin.
There was a 90 % rate of successful fistula closures (9 of
10) in this retrospective analysis of early-onset BoNT
Fig. 1 A patient with a right-sided permanent fistula (blue arrow).
Parotid surgery had been done more than 1 year earlier. Regularly
occurring discharge of saliva after gustatory stimuli
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therapy. Our current therapeutic approach as described here
in a larger number of patients confirms previous observa-
tions of other authors [3, 4, 6, 9–12, 16]. The results could
indicate that the local conditions for fistula healing are
improved by the reduction of salivary production, and clo-
sure of the fistula may only have become possible due to the
application of BoNT.
In addition, reducing the volume of the aggressive agent
“saliva” produced in the remaining glandular tissue might
allow the fistula to heal earlier, i.e., the treatment might
affect the time factor. In the present analysis, closure of
the fistulas was achieved in the time frame of 2 to 5 weeks.
In this study, we described a cohort of 12 patients, and it is
important to state that a larger study with more patients with
this rare complication will be helpful in the future. In this
connection, it will be of interest to perform such a study
including a matched untreated group with spontaneous
closure.
The reduction of salivary flow that occurs within a few
days after the injection as described in numerous publica-
tions [4, 6, 9, 10, 12, 16] must not be equated with the end of
wound healing. Nevertheless, this is a very important effect
since it alleviates the patients’ symptoms and reduces the
discomfort associated with saliva draining through the fis-
tula and running down the cheek and neck. Even if fistula
closure cannot be achieved, this is still a very positive effect
of the BoNT injection since it eliminates the visible social
stigma.
Improvement is also possible with permanent fistulas
even if fistula closure cannot be achieved. Guntinas and
Sittel reported that salivary flow from a permanent fistula
ceased for up to 11 months after BoNT application [4]. This
indicates that BoNT is at least a rapidly acting symptomatic
treatment.
There are, at present, no standardized dose recommenda-
tions for this indication, but the doses we used showed an
adequate effect. They were relatively high compared to the
dose normally used to treat hypersalivation (22.5 U of
Botox® for each gland, ref. [3]) considering the reduced
size of the glandular compartment. Lim and Choi [9] point
out that lower doses of BoNT are effective if the substance is
correctly injected into the glandular tissue. This was ensured
in our patients by the ultrasound-guided injection technique
[3]. It should also be noted that our chosen dosage is similar
to that described by other authors [6, 9, 10, 12].
In summary, our experience shows that when dealing
with fistulas subsequent to parotidectomy, it is therapeuti-
cally relevant to distinguish between early and permanent
fistulas. Treatment of parotidectomy-associated salivary fis-
tulas with botulinum toxin A should commence early. It is
our opinion that the most important aspect of BoNT therapy
is the reduction of saliva production in the remaining glan-
dular tissue as this seems to have a positive effect on the
healing process. The resulting potential shortening of the
healing period and the confirmed immediate reduction of
saliva drainage over the parotid region and neck [3, 4, 6, 9,
10, 12, 13, 16] are great advantages for the patient with
regard to local side effects and the social stigma. This argues
for the early use of BoNT, regardless of an ultimate closure
of the fistula. Our observations show that there is a good
chance of healing (9 out of 10, 90 %) after early treatment
with BoNT.
Permanent fistulas pose special problems for treatment
[1, 6, 16]. Radiation therapy should be considered as a last
resort [2].
The flow diagram in Fig. 2 illustrates our current thera-
peutic approach. We agree with Marchese-Ragona et al. [11,
12] that further prospective studies with BoNT with a
Fig. 2 Our therapy regimen for the treatment of salivary fistulas. The strategy shown here is aimed at fistula closure
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greater number of patients should be conducted to confirm
and optimize the therapy with regard to effective dose and
timing.
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